TL

Tri Locum Partners

North America, New York, United States, New York

Description

Tri Locum is a healthcare investment firm with SEC registration committed to making investments in both public and private opportunities.

Investor Profile

Tri Locum Partners has backed more than 2 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.

Stage Focus

  • Post Ipo Equity (50%)
  • Series C (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Genetics
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tri Locum Partners frequently co-invest with?

Blue Owl
North America, New York, United States, New York
Co-Investments: 1
LabCorp
North America, North Carolina, United States, Burlington
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
GM
North America, New York, United States, New York
Co-Investments: 1
Bio-Rad Laboratories
North America, California, United States, Hercules
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
LC
North America, Missouri, United States, St Louis
Co-Investments: 1
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 1
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1

What are some of recent deals done by Tri Locum Partners?

Geneoscopy

Saint Louis, Missouri, United States

Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.

BiotechnologyGeneticsHealth CareHealth Diagnostics
Series CJan 8, 2025
Amount Raised: $105,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityApr 18, 2024
Amount Raised: $70,000,000